Serotonin reuptake inhibitor antidepressants, including selective serotonin reuptake
inhibitors (SSRIs; ie, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and …

The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly
polymorphic human CYP2D6 gene locus. CYP2D6 genetic variation impacts the metabolism …

Translating CYP 2D6 genotype to metabolizer phenotype is not standardized across clinical
laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines …

Purpose: Owing to its highly polymorphic nature and major contribution to the metabolism
and bioactivation of numerous clinically used drugs, CYP2D6 is one of the most extensively …

Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for well‐known …

Pharmacogenomics is a key component of personalized medicine that promises safer and
more effective drug treatment by individualizing drug choice and dose based on genetic …

Phenoconversion is a phenomenon that converts genotypic extensive metabolizers (EM s)
into phenotypic poor metabolizers (PM s) of drugs, thereby modifying their clinical response …

The seminal paper on the CYP2D6 Activity Score (AS) was first published ten years ago
and, since its introduction in 2008, it has been widely accepted in the field of …

The CYP2D6 gene encodes an enzyme important in the metabolism of many commonly
used medications. Variation in CYP2D6 is associated with inter-individual differences in …

Introduction: The frequency of CYP2D6 alleles, related to either a lack of or increased
enzymatic activity, which may lead to poor metabolism (PM) or ultrarapid metabolism (UM) …